ad

Alpa Laboratories Analyst Review 2027: Sales Rise 10% but Q2 Swings to a Loss

19 Nov 2026 • 2:19 pm

Alpa Laboratories Analyst Review 2027: Sales Rise 10% but Q2 Swings to a Loss

Alpa Laboratories Stock Snapshot (18 Nov 2026 close)

  • Current Market Price (CMP): ₹51.59
  • 52-Week High / Low: ₹92.50 / ₹46.10
  • Market Capitalisation: ₹109 crore
  • P/E Ratio vs Industry P/E: 51.6 vs 40.1
  • Latest Quarter (Q2 FY27) Revenue: ₹32.22 crore
  • Latest Quarter (Q2 FY27) Net Profit: Loss of ₹1.85 crore

Quick Answer: The Alpa Laboratories analyst review 2027 finds no brokerage coverage as of November 2026. Q2 FY27 sales rose about 10% to ₹32.22 crore, but EBITDA turned negative at minus ₹0.99 crore and the company posted a net loss of ₹1.85 crore, against a small profit a year ago. FY26 revenue was ₹121.6 crore with profit of ₹15 crore. The stock closed at ₹51.59, about 44% below its 52-week high, and trades at about 0.58 times book value, so the Alpa Laboratories share price target 2027 question depends on a return to operating profit.

The Alpa Laboratories analyst review 2027 covers an Indore-based maker of finished medicines such as injections, tablets, capsules and ointments, sold under its own brand, through contract manufacturing and in export markets. Readers searching for an Alpa Laboratories share price target 2027 will not find a named brokerage figure, so results and book value guide this review.

Alpa Laboratories closed at ₹51.59 on 18 November 2026, about 44% below its 52-week high of ₹92.50 and about 12% above its low of ₹46.10. This Alpa Laboratories analyst review 2027 covers the September quarter and the Alpa Laboratories stock outlook 2027.

Click Here – Get Free Investment Predictions

What Analysts Say in the Alpa Laboratories Analyst Review 2027

Brokerage Rating Target Price Date
No verified coverage Not available Not available As of November 2026

No brokerage covers Alpa Laboratories, and institutions hold less than 0.5% of the company. With a market value of about ₹109 crore, it sits outside research coverage.

Book value is the clearest reference point. Book value per share is about ₹88.36, well above the share price, so the market values the company at about 0.58 times net worth. This Alpa Laboratories analyst review 2027 explains why that discount has widened.

Q2 FY27 Results in the Alpa Laboratories Analyst Review 2027

Quarter Revenue EBITDA Net Profit
Sep 2026 (Q2 FY27) ₹32.22 crore Minus ₹0.99 crore Loss of ₹1.85 crore
Jun 2026 (Q1 FY27) ₹29.70 crore ₹1.81 crore ₹0.98 crore
Mar 2026 (Q4 FY26) ₹31.24 crore ₹3.44 crore ₹1.38 crore
Dec 2025 (Q3 FY26) ₹29.96 crore ₹2.42 crore ₹1.59 crore
Sep 2025 (Q2 FY26) ₹29.32 crore ₹0.82 crore ₹0.11 crore

Revenue rose about 10% from a year ago and about 8% from the June quarter, but EBITDA turned negative at minus ₹0.99 crore. The company posted a net profit loss of ₹1.85 crore, its weakest quarter in the table.

Higher sales with an operating loss points to cost pressure, such as raw materials, staff or new capacity costs. For this Alpa Laboratories analyst review 2027, the December quarter will show whether this was a one-off.

How Alpa Laboratories Makes Money

Alpa makes finished dosage forms at its plant near Indore.

  • Own brand: generic, over-the-counter and veterinary medicines sold under the Alpa name.
  • Contract manufacturing: production for other pharma companies.
  • Injections and liquids: liquid and dry powder injections, among other forms.
  • Exports: sales to markets in Africa, Asia and Latin America.

FY26 revenue was about ₹121.6 crore with profit of about ₹15 crore, against ₹135.8 crore and ₹19.5 crore in FY25. Operating cash flow was about ₹9.3 crore in FY26. Those numbers frame this Alpa Laboratories analyst review 2027.

Annual profit has been much higher than recent quarters suggest. The four quarters from December 2025 to September 2026 add up to only about ₹2.1 crore of profit, compared with ₹15 crore for FY26 as a whole. That points to a large contribution from one earlier quarter or from non-operating income, so the core business currently earns far less than the annual figure implies.

Small formulation makers face pricing pressure from larger rivals, and contract manufacturing margins depend on how fully the plant is used. Export orders can also be lumpy, so revenue and margins can move sharply between quarters.

The company has been carrying out a capital spending programme to add capacity. New capacity often adds costs before it adds revenue, so margins could stay under pressure until the expansion starts contributing to sales.

The balance sheet is almost debt-free, with debt to equity of about 0.01, so the losses do not create immediate financial strain. The issue is return on equity, which has fallen to about 1.1%, the main reason the stock trades well below book.

Growth Triggers in the Alpa Laboratories Analyst Review 2027

  • Sales growth: Q2 FY27 revenue up about 10%.
  • Debt-free: debt to equity near zero.
  • Capacity additions: new capacity could lift volumes over time.
  • Export reach: sales across several emerging markets.
  • Discount to book: about 0.58 times book feeds the Alpa Laboratories share price target 2027 debate.

Key Risks in the Alpa Laboratories Analyst Review 2027

  • Operating loss: EBITDA turned negative in Q2 FY27.
  • Weak core earnings: about ₹2.1 crore profit over four quarters.
  • Low returns: return on equity of about 1.1%.
  • Pricing pressure: competition from larger drug makers.
  • Share price fall: about 44% below its high, a caution in the Alpa Laboratories analyst review 2027.

Compare Alpa Laboratories With Other Pharma Stocks on the Univest Screener

Alpa Laboratories Analyst Review 2027: Stock at a Glance

Metric Value
Share Price (18 Nov 2026 close) ₹51.59
52-Week High / Low ₹92.50 / ₹46.10
Market Capitalisation ₹109 crore
P/E (TTM) 51.6
Price to Book 0.58
Book Value per Share ₹88.36
Return on Equity 1.1%
Debt to Equity 0.01
EPS (TTM) ₹1.00
FY26 Revenue / Net Profit ₹121.6 crore / ₹15.0 crore

The P/E of about 52 looks high only because trailing earnings have fallen sharply. Price to book value of 0.58 is the more useful measure. In this Alpa Laboratories analyst review 2027, returns need to recover before the discount can narrow.

Shareholding Trend

Holder Sep 2025 Sep 2026 Change
Promoters 57.29% 57.19% Down 0.10 points
Foreign Investors (FII) 0.35% 0.35% No change
Domestic Institutions (DII) 0.00% 0.07% Up 0.07 points
Public 42.35% 42.39% Flat

The promoter group holds about 57.2%, led by managing director Paresh Chawla at 34.3% and Shitul Shah at 10.2%. Stable holdings are a neutral point in the Alpa Laboratories analyst review 2027.

Univest iOS App

Univest Android App

What to Watch After the Alpa Laboratories Analyst Review 2027

  • December quarter: a return to positive EBITDA.
  • Margins: recovery towards earlier levels.
  • Capacity: progress on the capital spending plan.
  • Exports and contracts: new orders that lift plant use.
  • Coverage: any research note would give an Alpa Laboratories share price target 2027 reference.

Final Word on the Alpa Laboratories Analyst Review 2027

The Alpa Laboratories analyst review 2027 shows a debt-free drug maker with growing sales but an operating loss in Q2 FY27 and weak core earnings. The stock trades near its 52-week low and well below book value.

The Alpa Laboratories stock outlook 2027 depends on restoring margins and lifting returns. Univest does not give a buy or sell call.

Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.

Frequently Asked Questions

What does the Alpa Laboratories analyst review 2027 show?

It shows higher sales but a loss. Q2 FY27 revenue rose about 10% to ₹32.22 crore, but the company posted a net loss of ₹1.85 crore. EBITDA was minus ₹0.99 crore.

Is there an Alpa Laboratories share price target 2027 from brokerages?

No brokerage covers Alpa Laboratories as of November 2026. The stock closed at ₹51.59 on 18 November 2026. Book value per share is about ₹88.36.

What does Alpa Laboratories make?

Alpa makes finished medicines such as injections, tablets, capsules and ointments at its Indore plant. It sells under its own brand, does contract manufacturing and exports. FY26 revenue was about ₹121.6 crore.

Why did Alpa Laboratories post a loss in Q2 FY27?

Operating costs rose faster than sales, turning EBITDA negative at minus ₹0.99 crore. Revenue still grew about 10%. The four quarters to September 2026 earned only about ₹2.1 crore in total.

Is Alpa Laboratories stock undervalued based on the Alpa Laboratories analyst review 2027?

The stock trades at about 0.58 times book value. Return on equity has fallen to about 1.1%. The P/E of about 52 reflects depressed earnings.

What risks does the Alpa Laboratories analyst review 2027 highlight?

The main risks are the operating loss, weak core earnings and pricing pressure. The stock is about 44% below its 52-week high of ₹92.50. Returns are very low.

What should investors track after the Alpa Laboratories analyst review 2027?

Track whether EBITDA turns positive in the December quarter. Watch margins, progress on new capacity and new export or contract orders. Return on equity also matters.

Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
for Startups Accelerator 2024

for Startups Accelerator 2024

Trusted by 1Cr Indians

Trusted by 1Cr Indians

Awarded No.1 by Economic Times

Awarded No.1 by Economic Times

GET THE APP

Join 1Cr users today.

SEBI Registered Analyst-backed Picks. Free Demat. One App

  • Free Demat account in under 5 minutes
  • Live market data — Nifty, Sensex, sector insights
  • SEBI Registered analyst-backed stock picks
Get it on Google PlayDownload on the App Store
Stocks:
All|a|b|c|d|e|f|g|h|i|j|k|l|m|n|o|p|q|r|s|t|u|v|w|x|y|z

Copyright 2026 Univest. All rights reserved.
Designed with ❤️ in India

arrow down